Page last updated: 2024-12-10

amyloid beta-peptides

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

amyloid beta-protein (29-40): a non-fibrillar portion of amyloid-beta protein [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

amyloid beta-protein (1-40): although acutely neurotoxic in both rat & monkey cerebral cortex, neuronal degeneration in primates resembles more closely to that found in Alzheimer's disease; amino acid sequence has been determined [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

amyloid beta-protein (1-28): binding of synthetic beta-amyloid peptide fragments to glycosaminoglycan is pH-dependent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131954553
MeSH IDM0024786
PubMed CID146156923
MeSH IDM0024786
PubMed CID139600448
MeSH IDM0024786
PubMed CID131954545
MeSH IDM0024786
PubMed CID91977102
MeSH IDM0024786

Synonyms (22)

Synonym
134500-80-4
AKOS034831546
amyloid beta-protein (1-43)
s-134500-80-4
PD079223
131580-10-4
amyloid beta-protein (1-16)
beta-amyloid (1-16)
beta-amyloid (29-40)
amyloid beta-protein (29-40)
|a-amyloid (1-40)
amyloid beta-protein (1-40)
beta-amyloid (1-40), rat
AKOS034831535
FT-0688951
beta-amyloid peptide (1-40) (human)
HB8758
c194h295n53o58s
PD079023
beta-amyloid (1-28)
amyloid beta-protein (1-28)
109770-29-8

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Substrate-bound Abeta peptides were found to be toxic to the cells and to increase the rate of cell death."( Toxicity of substrate-bound amyloid peptides on vascular smooth muscle cells is enhanced by homocysteine.
Barrow, CJ; Beyreuther, K; Masters, CL; Mok, SS; Small, DH; Turner, BJ, 2002
)
0.31
" The results revealed that beta AP1-40 was significantly more toxic than both reverse peptide and the vehicle."( The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected beta-amyloid in the rat brain.
Emre, M; Geula, C; Mesulam, MM; Ransil, BJ,
)
0.13
" Toxic forms of A beta rapidly inactivate the oxidation-sensitive cytosolic enzyme glutamine synthetase (GS)."( Enhancement of beta-amyloid peptide A beta(1-40)-mediated neurotoxicity by glutamine synthetase.
Aksenova, MV; Butterfield, DA; Carney, JM; Harris, ME; Hensley, K, 1995
)
0.29
" These results suggest that by binding beta-amyloid these compounds may prevent toxic interactions of the peptide with cells."( Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells.
Hawtin, SR; Pollack, SJ; Sadler, II; Shearman, MS; Tailor, VJ, 1995
)
0.29
"We recently reported that several sulfate-containing glycosaminoglycans, a class of compounds associated with the beta-amyloid plaques of Alzheimer's disease, attenuate the toxic effects of beta-amyloid fragments beta 25-35 and beta 1-40."( Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion.
Hawtin, SR; Pollack, SJ; Sadler, II; Shearman, MS; Tailor, VJ, 1995
)
0.29
" Our results show that both A beta(1-42) and A beta(25-35) are toxic to HAEC in a time- and dose-dependent manner, and that this toxicity can be partially prevented by the calcium channel blocker, verapamil, and the antioxidant, superoxide dismutase."( Superoxide free radical and intracellular calcium mediate A beta(1-42) induced endothelial toxicity.
Crawford, F; Fang, C; Mullan, M; Suo, Z, 1997
)
0.3
" To use this test, the toxic concentration(s) of betaA4 must first be established empirically."( Predicting the in vitro toxicity of synthetic beta-amyloid (1-40).
Brining, SK,
)
0.13
" Additionally, cultured fetal rat cortical neurons are less vulnerable to the toxic actions of aged A beta following pretreatment with alpha2M."( Alpha2-macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons.
Bales, KR; Dodel, RC; Du, Y; Glinn, MA; Horn, JW; Little, SP; Liu, X; Paul, SM, 1998
)
0.3
" Fibrillar Abeta at plaque-equivalent concentrations is not toxic in the young adult rhesus brain."( Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity.
Geula, C; Lorenzo, A; Saroff, D; Wu, CK; Yankner, BA; Yuan, M, 1998
)
0.3
" Stable AChE-Abeta complexes were found to be more toxic than those formed without the enzyme, for Abeta1-40 and Abeta1-42, but not for amyloid fibrils formed with AbetaVal18-Ala, a synthetic variant of the Abeta1-40 peptide."( Neurotoxicity of acetylcholinesterase amyloid beta-peptide aggregates is dependent on the type of Abeta peptide and the AChE concentration present in the complexes.
Inestrosa, NC; Muñoz, FJ, 1999
)
0.3
" However, rather than protecting cultured neurons against Abeta(1-40) toxicity, alphaB-crystallin actually increases the toxic effect."( The molecular chaperone alphaB-crystallin enhances amyloid beta neurotoxicity.
Boelens, WC; Bosman, GJ; de Jong, WW; Overkamp, PS; Reijnen-Aalbers, A; Renkawek, K; Stege, GJ; van Rijk, AF; Verschuure, P, 1999
)
0.3
" Based upon previous in vitro studies regarding A beta N-terminal truncated isoforms, it has been hypothesized that A beta3(pE)-x isoforms may aggregate more rapidly and become more toxic than corresponding Abeta1-x peptides."( Toxicity of pyroglutaminated amyloid beta-peptides 3(pE)-40 and -42 is similar to that of A beta1-40 and -42.
Geddes, JW; Glabe, C; Tekirian, TL; Yang, AY, 1999
)
0.3
" This peptide has been shown to be toxic to several relevant cell types, including neurons, cerebrovascular smooth muscle cells, and endothelial cells."( Toxicity of various amyloid beta peptide species in cultured human blood-brain barrier endothelial cells: increased toxicity of dutch-type mutant.
Davies, TA; Eisenhauer, PB; Fine, RE; Johnson, RJ; Wells, JM, 2000
)
0.31
" In addition, G protein inhibitors significantly reduced the toxic effects of the amyloidogenic Abeta and calcitonin peptides."( The role of G protein activation in the toxicity of amyloidogenic Abeta-(1-40), Abeta-(25-35), and bovine calcitonin.
Good, TA; Rymer, DL, 2001
)
0.31
" Here we examine the effects of N-acetyl-L-cysteine (NAC) on beta-amyloid (A beta) secretion and tau phosphorylation in SHSY5Y neuroblastoma cells after exposure to oxidative stress inducing/cytotoxic compounds (H(2)O(2), UV light and toxic A beta peptides)."( N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta-amyloid secretion and tau phosphorylation.
Baysang, G; Brack, C; Brockhaus, M; Meier, F; Müller-Spahn, F; Olivieri, G; Stähelin, HB, 2001
)
0.31
" The beta-amyloid fragment A beta(1-40) is toxic to rat pheochromocytoma PC12 cells, leading to a concentration-dependent decrease in the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)."( Effect of zinc ions on the cytotoxicity induced by the amyloid beta-peptide.
Moreira, P; Oliveira, C; Pereira, C; Santos, MS, 2000
)
0.31
" These results suggest that Abeta is toxic only in the matured adult brain, and that the mechanism of toxicity is related to NGF synthesis."( Difference in toxicity of beta-amyloid peptide with aging in relation to nerve growth factor content in rat brain.
Fukuta, T; Furukawa, S; Itoh, A; Nabeshima, T; Nitta, A, 2001
)
0.31
" Catalase or vitamin E showed no protective effect against betaA25-35 Dithiothreitol (DTT), N-acetylcysteine (NAC) and cyclosporine A significantly prevented the toxic effects of both betaA25-35 and peroxide, while inhibition of peroxide detoxifying enzymes enhanced toxicity."( beta-Amyloid-induced cytotoxicity, peroxide generation and blockade of glutamate uptake in cultured astrocytes.
Brera, B; de Ceballos, ML; Fernández-Tomé, MP, 2001
)
0.31
" In neurons from old rats, high levels of TNF together with Abeta are more toxic than in neurons from middle-age or embryonic rats."( Age- and concentration-dependent neuroprotection and toxicity by TNF in cortical neurons from beta-amyloid.
Brewer, GJ; McManus, DQ; Smith, SS; Viel, JJ, 2001
)
0.31
" In the present study, we directly address whether intracellular Abeta is toxic to human neurons."( Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons.
Goodyer, C; LeBlanc, A; McLaughlin, R; Zhang, Y, 2002
)
0.31
" We observed that Abeta(Glu22-->Gln) fibrils are more toxic for vascular cells than the wild-type fibrils."( Vitamin E but not 17beta-estradiol protects against vascular toxicity induced by beta-amyloid wild type and the Dutch amyloid variant.
Fernández, V; Gil-Gómez, G; Inestrosa, NC; Muñoz, FJ; Opazo, C; Tapia, G; Valverde, MA, 2002
)
0.31
"Amyloid-beta-protein (betaA/4, AbetaP) accumulates in the brains of patients with Alzheimer's disease (AD), regardless of genetic etiology, and is thought to be the toxic principle responsible for neuronal cell death."( Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-beta-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site.
Arispe, N; Lee, G; Pollard, HB, 2002
)
0.31
" Pre-treatment of the cells with alpha-estradiol did not alleviate the toxic effects of the heavy metals."( The effects of beta-estradiol on SHSY5Y neuroblastoma cells during heavy metal induced oxidative stress, neurotoxicity and beta-amyloid secretion.
Baysang, G; Brockhaus, M; Meier, F; Müller-Spahn, F; Novakovic, M; Olivieri, G; Savaskan, E, 2002
)
0.31
"Cell degeneration in Alzheimer's disease is mediated by a toxic mechanism that involves interaction of the AbetaP peptide with the plasma membrane of the target cell."( Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) peptides.
Arispe, N; Doh, M, 2002
)
0.31
" Abeta peptides were also toxic to vascular smooth muscle cells."( Cholesterol is necessary both for the toxic effect of Abeta peptides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes.
Aguilar, MI; Barrow, CJ; Mok, SS; Small, DH; Subasinghe, S; Unabia, S, 2003
)
0.32
" Thus, it appears that the toxic species of Abeta1-40 is most likely the same transient activated monomer that is responsible for the nucleation of fibril formation."( Spontaneous aggregation and cytotoxicity of the beta-amyloid Abeta1-40: a kinetic model.
Buhl, AE; Epps, DE; Fici, G; Kappenman, K; Kawabe, T; Lutzke, BS; Molinari, A; Poorman, RA; Sarver, RW; Taylor, BM, 2003
)
0.32
"beta-Amyloid peptide (beta-AP) elicits a toxic effect on neurons in vitro and in vivo."( Synergistic protection of PC12 cells from beta-amyloid toxicity by resveratrol and catechin.
Conte, A; Pellegrini, S; Tagliazucchi, D, 2003
)
0.32
" Our results predict that only cells containing appreciable levels of tau are susceptible to Abeta-induced toxicity and may explain why Abeta is more toxic to neurons compared with other cell types."( Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression.
Atwood, CS; Chan, HW; Liu, T; Martins, RN; Perry, G; Smith, MA; Verdile, G, 2004
)
0.32
"The underlying cause of Alzheimer's disease is thought to be the aggregation of monomeric beta-amyloid (Abeta), through a series of toxic oligomers, which forms the mature amyloid fibrils that accumulate at the center of senile plaques."( Both the D-(+) and L-(-) enantiomers of nicotine inhibit Abeta aggregation and cytotoxicity.
Allsop, D; El-Agnaf, OM; Fullwood, NJ; Gibson, GL; Huckerby, TN; Moore, SA; Tabner, BJ; Turnbull, S, 2004
)
0.32
" These results suggest that donepezil exerts a neuroprotective effect by reducing the amount of the toxic form of Abeta fibrils in septal neuron cultures."( Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons.
Akasofu, S; Kimura, M; Ogura, H; Sawada, K, 2005
)
0.33
" These results provide additional evidence that aggregation of Abeta into soluble oligomeric forms is a pathological step in AD and that Abeta42 in particular is more susceptible to forming these toxic oligomers than Abeta40."( Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42.
Barkhordarian, H; Emadi, S; Liu, R; Park, CB; Sierks, MR, 2005
)
0.33
" We have recently shown that Abeta peptides exert a time- and concentration-dependent toxic effect on rat neuromicrovascular endothelial cells (NECs), and this study aimed to ascertain whether ApoE isoforms are able to modulate this effect."( Apolipoprotein-E modulates the cytotoxic effect of beta-amyloid on rat brain endothelium in an isoform-dependent specific manner.
Baiguera, S; De Carlo, E; Di Liddo, R; Folin, M; Grandi, C; Guidolin, D; Nussdorfer, GG; Parnigotto, PP, 2006
)
0.33
" It was the aim of our study to investigate if these and other sHsps bind to wild-type Abeta1-42 or the more toxic Abeta1-40 carrying the 'Dutch' mutation (22Glu-->Gln) (D-Abeta1-40), affect Abeta aggregation and thereby influence Abeta cytotoxicity."( Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity.
Boelens, WC; de Waal, RM; Kamps, B; Otte-Höller, I; Verbeek, MM; Wilhelmus, MM, 2006
)
0.33
" Here, we analyzed whether the ER-mediated apoptotic pathway is involved in the toxic effect of synthetic PrP and Abeta peptides."( An endoplasmic-reticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity.
Costa, R; Ferreiro, E; Oliveira, CR; Pereira, CM; Resende, R, 2006
)
0.33
"The key pathogenic event in the onset of Alzheimer's disease (AD) is believed to be the aggregation of the beta-amyloid (Abeta) peptide into toxic oligomers."( N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure.
Amijee, H; Doig, AJ; Kokkoni, N; Mason, JM; Stott, K, 2006
)
0.33
" An alternative explanation is based on the observation that certain amyloid fibril morphologies are more toxic than others, indicating that not all amyloid fibrils are equally toxic."( Surface structure of amyloid-beta fibrils contributes to cytotoxicity.
Akagi, T; Takashima, A; Yoshiike, Y, 2007
)
0.34
" Our previous structural analyses of Abeta42 suggested that Tyr10 and Met35 are brought closer together by the turn at positions 22 and 23, and the S-oxidized radical cation at position 35, which is the ultimate toxic radical species, can be produced effectively through oxidation by the phenoxy radical at position 10."( Distance measurement between Tyr10 and Met35 in amyloid beta by site-directed spin-labeling ESR spectroscopy: implications for the stronger neurotoxicity of Abeta42 than Abeta40.
Hara, H; Irie, K; Masuda, Y; Murakami, K; Ohigashi, H, 2007
)
0.34
" Compared with cortical neuron cultures from wild-type mice, cultures from Ngb-overexpressing transgenic (Ngb-Tg mice) were resistant to the toxic effects of NMDA and Abeta(25-35), as measured by polarization of cell membrane lipid rafts, mitochondrial aggregation, lactate dehydrogenase release, and nuclear fragmentation."( Neuroglobin attenuates beta-amyloid neurotoxicity in vitro and transgenic Alzheimer phenotype in vivo.
Banwait, S; Greenberg, DA; Jin, K; Khan, AA; Mao, XO, 2007
)
0.34
" With the possible exception of headache, no clinically significant adverse events or laboratory changes were observed."( Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.
Dean, RA; Farlow, MR; Ferguson-Sells, L; Friedrich, S; Gonzales, C; May, PC; Siemers, ER,
)
0.13
" Our results showed that Abeta (1-40) was more toxic than Abeta (25-35) and the cytotoxicity of Abeta was proportional to its concentration."( Examining the levels of ganglioside and cholesterol in cell membrane on attenuation the cytotoxicity of beta-amyloid peptide.
Chang, Y; Chen, LY; Chen, WY; Lin, MS; Wang, SS, 2008
)
0.35
" Incubated (fibrillar) RCMκ-CN was more toxic to PC12 cells than native RCMκ-CN with the highest level of toxicity being associated with mature fibrils and protofibrils."( αB-Crystallin inhibits the cell toxicity associated with amyloid fibril formation by κ-casein and the amyloid-β peptide.
Carver, JA; Dehle, FC; Ecroyd, H; Musgrave, IF, 2010
)
0.36
" Aβ showed toxic effects on primary rat brain endothelial cells measured by MTT dye conversion and the lactate dehydrogenase release."( Protection of the blood-brain barrier by pentosan against amyloid-β-induced toxicity.
Abrahám, CS; Csete, M; Csiszár, B; Deli, MA; Fülöp, L; Kittel, A; Niwa, M; Penke, B; Sipos, A; Szalai, A; Tóth, A; Veszelka, S, 2010
)
0.36
" Efforts at rational drug design, however, are hampered by uncertainties about the precise nature of the toxic aggregate."( Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's Aβ peptide and reduce its cytotoxicity.
Armstrong, AH; Chen, J; Hecht, MH; Koehler, AN, 2010
)
0.36
" These results suggest that Aβ₁₋₄₀-induced activation of PTK/MEK/ERK pathway in THP-1 monocytes leads to the release of inflammatory factors that are toxic to SK-N-SH cells and might contribute to the onset of AD."( ERK pathway activation is required for amyloid-β(1-40)(-)induced neurotoxicity of THP-1 human monocytes towards SK-N-SH neuroblastoma.
Chu, YQ; Li, L; Li, W; Yin, LL, 2011
)
0.37
"Dendrimers have been proved to interact with amyloids, although most of dendrimers assayed in amyloidogenic systems are toxic to cells."( Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid-dendrimer aggregates morphology and cell toxicity.
Appelhans, D; Benseny-Cases, N; Cladera, J; Gella, A; Klementieva, O; Voit, B, 2011
)
0.37
" These phenomena are mainly because that the strong interactions between copper and Aβ42 lead to great conformation changes, and stabilize Aβ42 aggregates at highly toxic nanoscale oligomer stage, whereas copper shows no similar impact on Aβ40."( Copper inducing Aβ42 rather than Aβ40 nanoscale oligomer formation is the key process for Aβ neurotoxicity.
Jin, L; Li, QY; Li, YM; Wu, WH; Zhao, YF, 2011
)
0.37
" A structure-function relationship between peptide aggregation state and toxic properties was established."( The molecular assembly of amyloid aβ controls its neurotoxicity and binding to cellular proteins.
Airoldi, C; Bigini, P; Bonetto, V; Cagnotto, A; Colombo, L; Diana, V; Lupi, M; Manzoni, C; Messa, M; Pignataro, M; Salmona, M; Sironi, E; Williams, A, 2011
)
0.37
" Plasma concentrations of ponezumab on day 261 at the no observed adverse effect level of 100 mg/kg were 22."( 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period.
Freeman, GB; Lin, JC; Pons, J; Raha, NM, 2012
)
0.38
" In this study we compared the effects of CB1 and CB2 receptor-selective ligands, the endocannabinoid anandamide and the phytocannabinoid cannabidiol, against oxidative stress and the toxic hallmark Alzheimer's protein, β-amyloid (Aβ) in neuronal cell lines."( Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro.
Harvey, BS; Mååg, JL; Musgrave, IF; Ohlsson, KS; Smid, SD, 2012
)
0.38
"Granular non-fibrillar aggregates (GNAs) are identified as possible toxic species in Alzheimer's disease."( Granular non-fibrillar aggregates and toxicity in Alzheimer's disease.
Benseny-Cases, N; Cladera, J; Klementieva, O; Malý, J, 2012
)
0.38
" We have used mixed neuronal-glial cerebellar cultures (NGCCs) and organotypic cerebellar cultures (OCCs) obtained from postnatal mice to assess the toxic effect of the Aβ oligomer 1-40 (Aβ1-40) after propidium iodide uptake in vitro."( Context-dependent toxicity of amyloid-β peptides on mouse cerebellar cells.
Aimar, P; Alasia, S; Lossi, L; Merighi, A, 2012
)
0.38
" The toxic nature of the Aβ(42) peptide in vivo can therefore be attributed to the higher kinetic stability of the oligomeric intermediate states that it populates relative to those of Aβ(40) rather than simply to its higher rate of aggregation."( Expression in drosophila of tandem amyloid β peptides provides insights into links between aggregation and neurotoxicity.
Barros, TP; Crowther, DC; Dobson, CM; Favrin, G; Imarisio, S; Jahn, TR; Lomas, DA; Luheshi, LM; Speretta, E; Tartaglia, GG, 2012
)
0.38
" The missing links on the pathway to Aβ oligomerization, fibril formation, and neurotoxicity in AD remain the identity of the toxic Aβ species and mechanism(s) of their toxicity."( Establishing the links between Aβ aggregation and cytotoxicity in vitro using biophysical approaches.
Jan, A; Lashuel, HA, 2012
)
0.38
"Clinical laboratory values, CSF cell counts, and magnetic resonance imaging scans were unchanged by treatment, and no adverse events could be clearly related to antibody administration."( Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.
Aisen, PS; Arnold, SE; Dean, RA; DeMattos, RB; Farlow, M; Friedrich, S; Gonzales, C; Mohs, R; Paul, SM; Porsteinsson, AP; Sethuraman, G; Siemers, ER; Snider, BJ; van Dyck, CH, 2012
)
0.38
"A combination of hydrophobic and electrostatic interactions is important in initiating the aberrant self-assembly process that leads to formation of toxic oligomers and aggregates by multiple disease-related proteins, including amyloid β-protein (Aβ), whose self-assembly is believed to initiate brain pathogenesis in Alzheimer's disease."( A key role for lysine residues in amyloid β-protein folding, assembly, and toxicity.
Bitan, G; Lopes, DH; Sinha, S, 2012
)
0.38
" Some of the toxic effects of amyloid-β are mediated through the interaction of the peptide with α7-type nicotinic acetylcholine receptors at the cell surface."( Acetylcholine and antibodies against the acetylcholine receptor protect neurons and astrocytes against beta-amyloid toxicity.
Abramov, AY; Holmström, KM; Kamynina, AV; Koroev, DO; Volpina, OM, 2013
)
0.39
" The full length Aβ as antigen might induce meningoencepholontis adverse effect since the middle and C-terminal fragments of Aβ contain T cell epitopes."( Anti-Aβ antibodies induced by Aβ-HBc virus-like particles prevent Aβ aggregation and protect PC12 cells against toxicity of Aβ1-40.
Feng, G; Jin, H; Qian, Y; Wang, W, 2013
)
0.39
" It is not clear how misfolding and aggregation of Aβ is affected in vivo by this mutation and whether this correlates with its toxic effects."( Expression of A2V-mutated Aβ in Caenorhabditis elegans results in oligomer formation and toxicity.
Bagnati, R; Bastone, A; Benussi, L; Catania, M; Di Fede, G; Diomede, L; Fiordaliso, F; Ghidoni, R; Gobbi, M; Paterlini, A; Romeo, M; Rossi, A; Salio, M; Salmona, M; Stravalaci, M; Tagliavini, F, 2014
)
0.4
"In Alzheimer's disease (AD), native Aβ protein monomers aggregate through the formation of a variety of water-soluble, toxic oligomers, ultimately leading to insoluble fibrillar deposits."( Investigation on the influence of (Z)-3-(2-(3-chlorophenyl)hydrazono)-5,6-dihydroxyindolin-2-one (PT2) on β-amyloid(1-40) aggregation and toxicity.
Arnesano, F; Calò, V; Campagna, F; Catto, M; De Stradis, A; Losacco, M; Palazzo, G; Purgatorio, R, 2014
)
0.4
" It was interesting to find that physcion was rather toxic to neuronal cells while albiflorin, aloeemodin and neohesperidin reduced the toxicity and ROS induced by both monomeric and oligomeric Aβ species."( Inhibition of β-amyloid Aggregation By Albiflorin, Aloeemodin And Neohesperidin And Their Neuroprotective Effect On Primary Hippocampal Cells Against β-amyloid Induced Toxicity.
Bian, Z; Ho, SL; Kwong, DW; Li, HW; Lin, C; Poon, CY; Wong, MS; Yan, T; Yung, KK, 2015
)
0.42
" Our results identify the Aβ tetramer, followed by the trimer, as the most toxic low-order oligomers Aβ species."( Membrane-bound tetramer and trimer Aβ oligomeric species correlate with toxicity towards cultured neurons.
Cappai, R; Ciccotosto, GD; Jana, MK; Pham, CL, 2016
)
0.43
" Furthermore, HWH, HK(C) H, and HAH act as very efficient inhibitors of copper-mediated reactive oxygen species (ROS) generation and prevent the copper-induced overproduction of toxic oligomers in the initial steps of amyloid aggregation in the presence of Cu(II) ions."( Histidine-Rich Oligopeptides To Lessen Copper-Mediated Amyloid-β Toxicity.
Caballero, AB; Espargaró, A; Gamez, P; Nicolás, E; Sabaté, R; Terol-Ordaz, L; Vázquez, G, 2016
)
0.43
" To test this, a nontoxic triphenylmethane dye, Brilliant Blue G (BBG), which has been reported to modulate Aβ aggregation and neurotoxicity, was investigated using mouse primary cortical neuronal cultures treated with photoinduced cross-linked toxic Aβ40 oligomers as well as soluble Aβ40 and Aβ42 peptides."( Oligomeric Amyloid-β Toxicity Can Be Inhibited by Blocking Its Cellular Binding in Cortical Neuronal Cultures with Addition of the Triphenylmethane Dye Brilliant Blue G.
Cappai, R; Ciccotosto, GD; Jana, MK, 2016
)
0.43
" The percentages of patients with treatment-emergent adverse events were similar in placebo (77."( A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.
Booth, K; Brashear, HR; Brody, M; Di, J; Liu, E; Lu, M; Margolin, RA; Novak, G; Shadman, A; Werth, JL, 2016
)
0.43
" Based on previous systematic proline replacement and solid-state NMR, we proposed a toxic dimer structure of Aβ42, a highly aggregative alloform, with a turn at positions 22 and 23, and a hydrophobic core in the C-terminal region."( Synthetic Models of Quasi-Stable Amyloid β40 Oligomers with Significant Neurotoxicity.
Akagi, KI; Hanaki, M; Hanaki, Y; Hirose, K; Irie, K; Irie, Y; Kawase, T; Monobe, Y; Murakami, K; Suzuki, T; Takai, T, 2017
)
0.46
" The primary objective was to assess the safety and tolerability of ABvac40 by registering all adverse events (AEs)."( Safety, tolerability and immunogenicity of an active anti-Aβ
Abdelnour, C; Badi, H; Boada, M; Buendía, M; Canudas, J; Casabona, D; Lacosta, AM; Lafuente, A; Marcos-Campos, I; Monleón, I; Munuera, J; Pascual-Lucas, M; Pérez-Grijalba, V; Pesini, P; Rodríguez-Gómez, O; Ruiz, A; San-José, I; Sarasa, L; Sarasa, M; Tárraga, L, 2018
)
0.48
" Toxic effect of oligomer was investigated in live SH-SY5Y neuroblastoma cells by characterizing cell morphology and cell mechanics using high-resolution AFM scanning."( Biophysical Characteristics of Human Neuroblastoma Cell in Oligomeric $\\beta $ -Amyloid (1-40) Cytotoxicity.
Fang, Y; Gao, Q; Lai, KWC; Li, HW; Yung, KKL; Zhang, S, 2018
)
0.48
"Intra-hippocampal microinjection of toxic Aβ40 (IHAβ40) by stereotaxic surgery was performed in the male Sprague-Dawley rats to generate an Aβ-induced AD model."( A Synthetic Pro-Drug Peptide Reverses Amyloid-β-Induced Toxicity in the Rat Model of Alzheimer's Disease.
Fatima, M; Giri, RS; Kumar, S; Mandal, B; Mondal, AC; Srivastav, S, 2019
)
0.51
" Abeta peptides were also toxic to vascular smooth muscle cells."( Cholesterol is necessary both for the toxic effect of Abeta peptides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes.
Aguilar, MI; Barrow, CJ; Mok, SS; Small, DH; Subasinghe, S; Unabia, S, 2003
)
0.32
" Prefibrillar species were more toxic than mature fibrils."( Dendrimers reduce toxicity of Aβ 1-28 peptide during aggregation and accelerate fibril formation.
Correa, J; Fernandez-Megia, E; Fernandez-Villamarin, M; Ionov, M; Klajnert, B; Riguera, R; Sousa-Herves, A; Wasiak, T, 2012
)
0.38
" The present results indicate that the fragment Aβ(1-28) contributes to aggregation, an increase in intracellular calcium and synaptotoxicity, but is not involved in membrane perforation; Aβ(25-35) is important for membrane perforation, calcium increase, and synaptotoxicity; and Aβ(17-42) induced mitochondrial toxicity similar to the full length Aβ(1-42), but was unable to induce membrane perforation and calcium increase, supporting the idea that it is less toxic in the non-amyloidogenic pathway."( Differential Membrane Toxicity of Amyloid-β Fragments by Pore Forming Mechanisms.
Aguayo, LG; Bascuñán, D; Opazo, C; Peters, C, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" [125I]Abeta(1-40) was eliminated from rat brain to circulating blood with a half-life of 48."( Brain insulin impairs amyloid-beta(1-40) clearance from the brain.
Hosoya, K; Kurihara, A; Naganuma, H; Nishimura, K; Ohtsuki, S; Shiiki, T; Tachikawa, M; Terasaki, T, 2004
)
0.32
"The goal of this study was to assess the tolerability profile, pharmacokinetic properties, and effects on pharmacodynamic markers (Aβ, trefoil factor family 3 protein, dual specificity phosphatase 6, and hairy and enhancer of split-1) of single, oral doses of avagacestat in healthy, young, male volunteers."( Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Albright, CF; Berman, RM; Castaneda, L; Croop, R; Dockens, RC; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2012
)
0.38
" PK following multiple doses (Part 2) were tmax of 1 to 3 h and mean t1/2 of 16 to 21 h across the 15 to 150 mg dose range."( AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.
Alexander, RC; Cebers, G; Eketjäll, S; Ereshefsky, L; Goldwater, R; Haeberlein, SB; Han, D; Kugler, AR; Maltby, J; Olsson, T; Rosen, L; Russell, M; Ye, N, 2017
)
0.46

Compound-Compound Interactions

ExcerptReferenceRelevance
"We validated the utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy (1H MRS) as an adjunct screening technique for dementia due to Alzheimer's disease (AD)."( Utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy as adjunct techniques for screening and predicting dementia due to Alzheimer's disease in clinical practice.
Arai, H; Fujii, C; Hata, S; Higuchi, S; Igarashi, K; Ishii, R; Iwai, N; Moriya, M; Ohrui, T; Suzuki, T; Tokuda, T; Uemura, K; Waragai, M; Yoshida, M, 2014
)
0.4
" We introduce ion mobility MS combined with multivariate statistics as a systematic approach to perform data analytics in drug discovery/amyloid research that aims at the evaluation of the inhibitory effect on the Aβ early assembly in vitro models at very low concentration levels of Aβ peptides."( Ion mobility spectrometry combined with multivariate statistical analysis: revealing the effects of a drug candidate for Alzheimer's disease on Aβ1-40 peptide early assembly.
Heeren, RMA; Lamont, L; Lazzaro, S; Ogrinc, N; Pappalardo, G; Vecchio, G, 2019
)
0.51
"Single blood TDP-43 could not estimate dementia occurrence; however, TDP-43 combined with demographics has the predictive effect for dementia occurrence and NfL level is associated with a decrease of cognitive function."( Blood TDP-43 Combined with Demographics Information Predicts Dementia Occurrence in Community Non-Dementia Elderly.
Li, W; Sun, L; Xiao, S; Yue, L, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" The mechanisms by which NADPH oxidase-derived radicals mediate the cerebrovascular dysfunction involve reduced bioavailability of nitric oxide."( NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide.
Anrather, J; Carlson, GA; Frys, K; Iadecola, C; Park, L; Pitstick, R; Younkin, S; Zhou, P, 2005
)
0.33
" These results demonstrate that MRK-560 is an orally bioavailable gamma-secretase inhibitor with the ability to markedly reduce Abeta peptide in the brain and CSF of the rat and confirm the utility of the rat for assessing the effects of gamma-secretase inhibitors on central nervous system Abeta(40) levels in vivo."( In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat.
Atack, JR; Best, JD; Churcher, I; Harrison, T; Jay, MT; Morentin-Gutierrez, P; Otu, F; Pattison, C; Reilly, M; Shearman, MS, 2006
)
0.33
", 1) with sufficient bioavailability and pharmacokinetic profiles to reduce central amyloid-β peptide (Aβ) levels in wild-type rats following oral dosing."( Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
Acton, P; Babu-Khan, S; Bartberger, MD; Brown, J; Chen, K; Cheng, Y; Citron, M; Croghan, MD; Dineen, TA; Dunn, RT; Esmay, J; Graceffa, RF; Harried, SS; Hickman, D; Hitchcock, SA; Horne, DB; Huang, H; Imbeah-Ampiah, R; Judd, T; Kaller, MR; Kreiman, CR; La, DS; Li, V; Lopez, P; Louie, S; Monenschein, H; Nguyen, TT; Patel, VF; Pennington, LD; San Miguel, T; Sickmier, EA; Vargas, HM; Wahl, RC; Weiss, MM; Wen, PH; Whittington, DA; Williamson, T; Wood, S; Xue, Q; Yang, BH; Zhong, W, 2012
)
0.38
" Our efforts resulted in the identification of a potent, orally bioavailable CNS penetrant compound that exhibited in vivo efficacy."( Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer's disease.
Chen, K; Cheng, AC; Dineen, TA; Epstein, O; Fremeau, RT; Graceffa, R; Hickman, D; Huang, H; Kiang, YH; La, DS; Louie, S; Luo, Y; Patel, VF; Wahl, RC; Wen, PH; Whittington, DA; Wood, S, 2012
)
0.38
" Reactive astrogliosis was reported in neuroanatomical structures of adaptive behaviors after a single RF EMF exposure at high specific absorption rate (SAR, 6 W/kg)."( Glial markers and emotional memory in rats following acute cerebral radiofrequency exposures.
Barthélémy, A; Blazy, K; Bouji, M; Mouchard, A; Puigsegur, R; Villégier, AS, 2016
)
0.43
" SEN1500, an orally bioavailable and CNS-penetrant Aβ aggregation inhibitor, has previously been shown to reduce spatial learning and memory deficits in an APP transgenic mouse model."( SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease.
Brunner, D; Duller, S; Flunkert, S; Hutter-Paier, B; Neddens, J; Scopes, DIC; Treherne, JM, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" In a recent report, we demonstrated that ApoE epsilon4 dosage correlates with an increase in A beta1-40 but not A beta1-42/43-immunoreactive plaques."( Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease.
Fraser, PE; Gearing, M; Ishii, K; Kato, M; Mirra, SS; Mizusawa, H; Mizutani, T; Mori, H; Ohtake, T; Shoji, S; St George-Hyslop, PH; Takahashi, H; Tamaoka, A; Tsuji, S; Yamada, S, 1997
)
0.3
"Patients with trisomy 21 [Down syndrome (DS)] progressively develop amyloid beta-protein (A beta) deposits and then other features of Alzheimer's disease (AD), apparently due to increased gene dosage and thus expression of the beta-amyloid precursor protein."( Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.
Blusztajn, JK; Lemere, CA; Saido, TC; Selkoe, DJ; Wisniewski, T; Yamaguchi, H, 1996
)
0.29
" We found significant cellular loss in the hippocampal regions of wild-type mice and dramatic rescue of neuronal cell death in caspase-3-deficient mice, with a gene dosage effect."( Amyloid beta peptide-induced cerebral neuronal loss is mediated by caspase-3 in vivo.
Kuida, K; Mori, H; Takuma, H; Tomiyama, T, 2004
)
0.32
" Accordingly, when all the data for the dose-response curve and time course were correlated, a strong association was observed between the brain and CSF Abeta(40) levels."( Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-di
Atack, JR; Best, JD; Ellis, S; Harrison, T; Jay, MT; Lewis, HD; Ma, J; Nadin, A; Otu, F; Pattison, C; Reilly, M; Shearman, MS; Williamson, TL, 2005
)
0.33
" To reveal any effect of cholinergic dysfunction on APP processing in vivo, 11-month-old transgenic Tg2576 mice with Abeta plaque pathology received intraperitoneal injections of scopolamine at a daily dosage of 2mg/kg body weight for 14 days in order to suppress cortical cholinergic transmission by chronic inhibition of muscarinic acetylcholine receptors."( Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein.
Liskowsky, W; Schliebs, R,
)
0.13
" This relationship between the brain and CSF Abeta was maintained when MRK-560 was dosed once a day for 2 weeks, and accordingly, when all the data for the dose-response curve and time courses were correlated, a strong association was observed between the brain and CSF Abeta levels."( In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat.
Atack, JR; Best, JD; Churcher, I; Harrison, T; Jay, MT; Morentin-Gutierrez, P; Otu, F; Pattison, C; Reilly, M; Shearman, MS, 2006
)
0.33
" Compounds that influence the elongation reaction are selected as hits and are tested in dose-response experiments."( Screening for modulators of aggregation with a microplate elongation assay.
Berthelier, V; Wetzel, R, 2006
)
0.33
" However, signs of neuronal stress including glial activation were observed in agent-treated retinas especially in high dosage groups."( Mitochondrial respiratory inhibition and oxidative stress elevate beta-secretase (BACE1) proteins and activity in vivo in the rat retina.
Cai, H; Clough, RW; Luo, XG; Struble, RG; Xiong, K; Yan, XX, 2007
)
0.34
" SPE sample preparation was also applied to the plasma of mice dosed peripherally with a monoclonal antibody raised against Abeta."( Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies.
Lanz, TA; Schachter, JB, 2008
)
0.35
" In this study, dosing of transgenic mice (J20 strain) with mutated human APP (Swedish mutations: K670N and M671L and Indiana mutation: V717F) transgene, with nicotine in drinking water for 20 weeks did not have a significant effect on total levels of Abeta 40 or 42 in hippocampus or cortex."( Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind).
Anand, K; Lue, LF; Reid, RT; Sabbagh, MN; Stadnick, T; Walker, DG, 2008
)
0.35
" Here we study GSI's effect on tumour and normal cellular processes to optimize dosing regimens for anti-tumour efficacy."( Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.
Angagaw, M; Bristow, L; Dai, X; Draetta, G; Efferson, C; Elbi, C; Gorenstein, J; Hardwick, J; Kenific, C; Kim, H; Kohl, NE; Kunii, K; Leach, KJ; Look, T; Majumder, PK; Nikov, G; O'Neil, J; Qu, X; Rao, S; Reilly, JF; Scott, M; Strack, PR; Tammam, J; Van der Ploeg, L; Ware, C; Winter, C; Zhao, J, 2009
)
0.35
"Inhibition of the Notch pathway in mouse intestinal epithelium was used to evaluate the effect of GSIs and guide the design of dosing regimens for xenograft models."( Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.
Angagaw, M; Bristow, L; Dai, X; Draetta, G; Efferson, C; Elbi, C; Gorenstein, J; Hardwick, J; Kenific, C; Kim, H; Kohl, NE; Kunii, K; Leach, KJ; Look, T; Majumder, PK; Nikov, G; O'Neil, J; Qu, X; Rao, S; Reilly, JF; Scott, M; Strack, PR; Tammam, J; Van der Ploeg, L; Ware, C; Winter, C; Zhao, J, 2009
)
0.35
" Two single-dose (140 mg), open-label, randomized, 3-period, crossover studies evaluated the effect of formulation, food, and time of dosing on the pharmacokinetics and pharmacodynamics of semagacestat in healthy participants."( Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants.
Annes, WF; Ayan-Oshodi, M; de la Peña, A; Friedrich, S; Lowe, SL; Sirois, PJ; Willis, BA; Zhang, W, 2012
)
0.38
" At the end of the dosing and recovery phases, plasma Aβ1-40 and Aβ1-x were increased in treated animals versus controls."( 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period.
Freeman, GB; Lin, JC; Pons, J; Raha, NM, 2012
)
0.38
" Prominent and long-lasting Aβ reductions in lumbar CSF were measured after oral dosing of 30 or 90 mg of LY2811376."( Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
Audia, JE; Boggs, LN; Calligaro, DO; Citron, M; Cocke, PJ; Dean, RA; Ereshefsky, L; Friedrich, S; Gonzales, CR; Greg Hall, D; Jhee, SS; Lindstrom, TD; Lowe, SL; Martenyi, F; Mathes, BM; May, PC; Mergott, DJ; Monk, SA; Nakano, M; Sheehan, SM; Smith Labell, E; Stout, SL; Timm, DE; Watson, BM; Yen, M, 2011
)
0.37
" Terminal brain, CSF and plasma Aβ levels measured at 24h after dosing demonstrated robust Aβ lowering and showed excellent correlation across these compartments."( Cisterna magna cannulated repeated CSF sampling rat model--effects of a gamma-secretase inhibitor on Aβ levels.
Price, EA; Sankaranarayanan, S; Shapiro, JS; Simon, AJ; Stiteler, M; Wu, G, 2012
)
0.38
" The expression of Abeta40 in hippocampus of all filial mice in various dosage groups was determined on the 21st day after birth by immunohistochemical assay."( [Effects of maternal lead exposure on the expression of Abeta40 in the hippocampus of the filial mice].
Li, N; Li, W; Qiao, M; Yang, G; Zhen, Y, 2011
)
0.37
"This was a multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study in 8 healthy young men (age, 18-45 years) per dosing panel."( Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Albright, CF; Berman, RM; Castaneda, L; Croop, R; Dockens, RC; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2012
)
0.38
"5 h after oral dosing (100 μmol/kg)."( New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in brain.
Blid, J; Bogar, K; Eketjäll, S; Fälting, J; Ginman, T; Gravenfors, Y; Janson, J; Jeppsson, F; Johansson, P; Karlström, S; Kihlström, J; Kolmodin, K; Lindström, J; Olsson, LL; Rahm, F; Slivo, C; Strömberg, K; Swahn, BM; Viklund, J; von Berg, S; von Kieseritzky, F, 2012
)
0.38
"Aβ 1-40 secretion in the presence of DAPT shows biphasic activation-inhibition dose-response curves."( Modulators of γ-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer's disease.
Popović, K; Šendula-Jengić, V; Svedružić, ŽM, 2013
)
0.39
" The CSF dosage of anti-Aβ autoantibodies with the technique here described can thus be proposed as a valid alternative tool for the diagnosis of CAA-ri."( Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.
Billo, G; Brioschi, M; Carriero, MR; Chiapparini, L; Colombo, A; DiFrancesco, JC; Ferrarese, C; Gardinetti, M; Giaccone, G; Greenberg, SM; Lanzani, F; Nitrini, R; Piazza, F; Piscosquito, G; Raicher, I; Sakaguchi, H; Savoiardo, M; Tagliavini, F, 2013
)
0.39
" Coexpression of mutant and wild-type PS1 at equal gene dosage in presenilin-deficient mouse embryo fibroblasts resulted in trans-dominant-negative inhibition of wild-type PS1 activity, suppressing γ-secretase-dependent cleavage of APP and Notch."( Trans-dominant negative effects of pathogenic PSEN1 mutations on γ-secretase activity and Aβ production.
Gutti, U; Heilig, EA; Kelleher, RJ; Shen, J; Tai, T, 2013
)
0.39
" Further investigation in a mouse model of human menopause indicates that chronic exposure to the phyto-β-SERM formulation at a clinically relevant dosage prevents/alleviates menopause-related climacteric symptoms."( Early intervention with an estrogen receptor β-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease.
Brinton, RD; Chen, S; Mao, Z; Schneider, LS; Zhao, L, 2013
)
0.39
"Development of novel therapeutic agents aimed at treating neurodegenerative disorders such as Alzheimer's and Parkinson's diseases require chronic and preferentially oral dosing in appropriate preclinical rodent models."( Alternative method of oral administration by peanut butter pellet formulation results in target engagement of BACE1 and attenuation of gavage-induced stress responses in mice.
Atchison, KP; Gonzales, C; Riddell, DR; Robshaw, A; Sukoff Rizzo, SJ; Zaleska, MM; Zhou, H, 2014
)
0.4
" However, it is unclear whether ibuprofen, within therapeutic dosing range, demonstrates GSM activity in humans."( Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans.
Galasko, DR; Golde, TE; Koo, EH; Ling, IF, 2015
)
0.42
" Following multiple doses, robust reductions in plasma (≥64% at 15 mg and ≥78% at ≥50 mg) and cerebrospinal fluid (≥51% at 15 mg and ≥76% at ≥50 mg) Aβ peptides were seen, including prolonged suppression even with a QW dosing regimen."( AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.
Alexander, RC; Cebers, G; Eketjäll, S; Ereshefsky, L; Goldwater, R; Haeberlein, SB; Han, D; Kugler, AR; Maltby, J; Olsson, T; Rosen, L; Russell, M; Ye, N, 2017
)
0.46
"Downregulation of abnormal Aβ influx across the BBB by FPS-ZM1 at higher dosage contributes to reduced neuronal apoptosis, improved hippocampal plasticity and cognitive impairment in db/db mice."( Targeted inhibition of RAGE reduces amyloid-β influx across the blood-brain barrier and improves cognitive deficits in db/db mice.
Chen, F; Du, YF; Hong, H; Hu, M; Long, Y; Reed, MN; Suppiramaniam, V; Tang, SS; Wang, H, 2018
)
0.48
"At low concentrations of Aβ40, dose-response associations with mortality differed between cohorts, possibly because of varying blood preparations used to measure Aβ40."( Amyloid-β (1-40) and Mortality in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: A Cohort Study.
Amrhein, C; Athanasouli, F; Badertscher, P; Biener, M; Boeddinghaus, J; Dimmeler, S; Gatsiou, A; Georgiopoulos, G; Giannitsis, E; Katus, HA; Mueller, C; Mueller-Hennessen, M; Nestelberger, T; Pateras, K; Sachse, M; Sopova, K; Stakos, D; Stamatelopoulos, K; Stellos, K; Twerenbold, R; Vafaie, M; Zeiher, AM, 2018
)
0.48
"Escitalopram significantly reduced Aβ in mice, similar to previous findings in humans treated with acute dosing of an SSRI."( Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model.
Cirrito, JR; Davis, TA; Doherty, BM; Gardiner, WD; King, D; Lee, JM; Sheline, YI; Wallace, CE; Yan, P; Yuede, CM, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,366)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.06)18.7374
1990's286 (8.50)18.2507
2000's1191 (35.38)29.6817
2010's1708 (50.74)24.3611
2020's179 (5.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials2 (2.53%)5.53%
Trials1 (9.09%)5.53%
Trials48 (1.47%)5.53%
Trials1 (1.30%)5.53%
Reviews4 (5.48%)6.00%
Reviews2 (2.53%)6.00%
Reviews1 (9.09%)6.00%
Reviews51 (1.57%)6.00%
Reviews0 (0.00%)6.00%
Case Studies2 (2.74%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies22 (0.68%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational11 (0.34%)0.25%
Observational0 (0.00%)0.25%
Other67 (91.78%)84.16%
Other75 (94.94%)84.16%
Other9 (81.82%)84.16%
Other3,125 (95.95%)84.16%
Other76 (98.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]